How big is the Europe Sodium-dependent Glucose Cotransporter 2 Market?

The Europe Sodium-dependent Glucose Cotransporter 2 Market size is expected to reach USD 1.30 billion in 2024 and grow at a CAGR of 9.10% to reach USD 2.02 billion by 2029. Read More

What is the current Europe Sodium-dependent Glucose Cotransporter 2 Market size?

In 2024, the Europe Sodium-dependent Glucose Cotransporter 2 Market size is expected to reach USD 1.30 billion. Read More

Who are the key players in Europe Sodium-dependent Glucose Cotransporter 2 Market?

Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals and Eli Lilly and Company are the major companies operating in the Europe Sodium-dependent Glucose Cotransporter 2 Market. Read More

What years does this Europe Sodium-dependent Glucose Cotransporter 2 Market cover, and what was the market size in 2023?

In 2023, the Europe Sodium-dependent Glucose Cotransporter 2 Market size was estimated at USD 1.18 billion. The report covers the Europe Sodium-dependent Glucose Cotransporter 2 Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Sodium-dependent Glucose Cotransporter 2 Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Europe Sodium-dependent Glucose Cotransporter 2 Market Share

Statistics for the 2023 & 2024 Europe Sodium-dependent Glucose Cotransporter 2 market share, created by Mordor Intelligence™ Industry Reports. Europe Sodium-dependent Glucose Cotransporter 2 share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Europe Sodium-dependent Glucose Cotransporter 2 Industry

The European SGLT-2 market is consolidated, with a few significant global manufacturers: Janssen, Eli Lilly, AstraZeneca, and Bristol Myers Squibb. The joint ventures that occurred between players in the recent past helped the companies strengthen their market presence. For example, Eli Lilly and Boehringer Ingelheim make Jardiance, a very popular SGLT-2 class drug.